Independent cancer report review for UK patients
For patients across England, Scotland, Wales and Northern Ireland seeking a scientific second read of their cancer reports. Kim Lockheimer, PhD, DFM reviews NHS genomic results, Signatera ctDNA reports and private panels, then prepares evidence and questions for your NHS or private consultant. This is clinical-scientist advisory, not a physician second opinion or a replacement for your care team.
What Kim reviews
- Pathology and tumor profiling (NGS) reports, including FoundationOne, Caris, Tempus and Guardant360
- Signatera and other ctDNA results
- Clinical trials that fit your molecular profile, locally and internationally
- Written questions and evidence your oncologist can act on
Price and scheduling
Every engagement starts with a free 15-minute call. No records or payment needed, and no obligation. The Clarity Report is USD $2,000 (about £1,600). Active Case Management: $4,500 / month; Concierge Advisory: $7,500 / month.
Video calls in GMT / BST. Paid receipts are suitable for Bupa, AXA Health, Vitality, and other private medical insurance reimbursement where policies allow.
All fees are in US dollars and payable online by card. Calls are scheduled to fit your time zone. Records in languages other than English may require translation before review.
Calls are with Kim Lockheimer, PhD, DFM, Chief Scientific Officer. Prices in local currency: /uk/pricing.
All fees are in US dollars and payable online by card. Calls are scheduled to fit your time zone. Records in languages other than English may require translation before review.
Remote scientific review, without traveling abroad. Kim Lockheimer, PhD, DFM is a clinical scientist, not a physician. Diagnosis, prescriptions and treatment decisions remain with your treating oncologist.
Signatera test in the UK: access, cost and what results mean
Signatera is a personalized ctDNA blood test built from your own tumor's mutations. Ask your treating consultant and the testing provider to confirm current UK ordering arrangements, NHS or trial access, and the complete cost before paying. Availability and funding can change.
A positive result means tumor DNA was detected, which can come before anything shows on a scan. A negative result is reassuring but does not rule out recurrence, and the timing and frequency of testing matter. Kim reviews the report, explains what the numbers mean in context, and prepares questions for your NHS or private oncologist.
NICE's 2022 Signatera innovation briefing (MIB307) identified uncertainty about effects on treatment decisions and patient outcomes. It is historical evidence, not a current NHS coverage decision. Detecting ctDNA earlier does not by itself prove that changing treatment earlier improves outcomes. Ask your consultant what evidence applies to your cancer and treatment setting today.
Guardant360 for UK patients
Guardant360 is a blood-based genomic test that looks for targetable mutations without a new biopsy. It can help when tissue is limited or a fresh biopsy is difficult, though it can miss changes when little tumor DNA is in the blood.
Kim checks whether a Guardant360 result fits with your NHS Genomic Medicine Service testing, whether anything actionable was found, and whether UK or EU trials match your profile.
Guides for patients
- Getting a private cancer second opinion in the UK
- Signatera test in the UK: access, cost and results
- Tumor profiling on the NHS
- Prostate cancer second opinion in the UK
Other regions
- Canadian patients
- Australian patients
- New Zealand patients
- Nigeria
- Kenya
- Israel
- the Philippines
- Pakistan
- Ghana
- the UAE and the Gulf
- Singapore
- Hong Kong
- Independent cancer NGS report review for patients in India
- Germany, Austria and Switzerland
- Ireland
- South Africa
- the Netherlands and the Nordics
- Latin America
- All international consultations